email article
Aggressively lowering blood pressure in hypertensive older adults did not consistently affect Alzheimer s imaging biomarkers, a substudy of SPRINT MIND participants showed.
MRI markers of Alzheimer s disease regional atrophy, cerebral blood flow, and mean fractional anisotropy were similar over 4 years whether patients had standard or aggressive blood pressure treatment, reported Ilya Nasrallah, MD, PhD, of University of Pennsylvania, and co-authors.
However, intensive blood pressure treatment was associated with a small but statistically significant larger decrease in hippocampal volume (mean difference -0.033 cm
3, 95% CI -0.062 to -0.003, P=0.03), they wrote in As vascular disease and Alzheimer s disease are the most common causes of cognitive decline in people of the age of those in the SPRINT study, we wanted to see whether brain biomarkers that are sensitive to these diseases could give a hint at whether either process was affected positivel
email article
Moderate fish consumption was associated with lower long-term cardiovascular disease (CVD) risk in high-risk individuals and those with existing vascular disease but not in the general population, according to a large pooled analysis.
In the largely CVD-naïve PURE study cohort, individuals who ate 350 g (or four servings of fish) a week were not better off than peers with little or no fish intake in terms of major CVD events (HR 0.95, 95% CI 0.86-1.04) or total mortality (HR 0.96, 95% CI 0.88-1.05) over a median 9.1 years of follow-up.
By contrast, moderate fish consumption at 175 g (two servings) per week was associated with reduced risk of major CVD (HR 0.84, 95% CI 0.73-0.96) and total mortality (HR 0.82, 95% CI 0.74-0.91) among the smaller ONTARGET, TRANSCEND, and ORIGIN cohorts of people with vascular disease or diabetes. Risk did not sink further with greater fish intake in this group.
email article
An FDA advisory committee turned thumbs down on Becton Dickinson s Lutonix 014 drug-coated balloon (DCB) for peripheral artery disease (PAD) during a virtual meeting on Wednesday.
Circulatory System Devices Panel members voted 14-3 (with one abstention) that the benefits of the investigational angioplasty catheter do not outweigh its risks as a treatment for patients with critical limb ischemia (CLI) who have obstructive de novo or non-stented restenotic lesions in below-the-knee (BTK) arteries.
Committee members were largely unconvinced that the Lutonix DCB was supported by adequate efficacy data.
In the pivotal Lutonix BTK IDE trial, the device showed a 10.5% absolute advantage in the primary efficacy endpoint (combined primary patency and limb salvage) at 6 months that was not significant under Bayesian analysis. Such improvement, if any, vanished by 12 months, and the endpoint started to favor the regular percutaneous transluminal angioplasty (PTA) arm by